Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)

Study acronym: ENHANCE-3
StatusNot Yet Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Merck (MSD)
410 trials monitored
See 27 trials at risk
COPD
1,120 trials monitored
See 36 trials at risk
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also evaluate the efficacy of ensifentrine compared with placebo in improving lung function, improving health related quality of life, and preventing severe exacerbations.
Trial Details
NCT Number NCT07874815
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Pulmonary Disease, Chronic Obstructive
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 2,136 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov